Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production

Michel L. Vandenplas, Russell W. Carlson, Benjamin S. Jeyaretnam, Brian McNeill, Michelle H. Barton, Natalie Norton, Thomas F. Murray, James N. Moore

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Endotoxin (lipopolysaccharide (LPS)), a component of Gram-negative bacteria, is among the most potent proinflammatory substances known. The lipid-A region of this molecule initiates the production of multiple host-derived inflammatory mediators, including cytokines (e.g. tumor necrosis factor-α (TNFα)). It has been a continuous effort to identify methods of interfering with the interaction between enteric LPS and inflammatory cells using natural and synthetic LPS analogs. Some of these LPS analogs (e.g. Rhodobacter spheroides LPS/lipid-A derivatives) are antagonists in human cells but act as potent agonists with cells of other species. Data reported here indicate that structurally novel LPS from symbiotic, nitrogen-fixing bacteria found in association with the root nodules of legumes do not stimulate human monocytes to produce TNFα. Furthermore, LPS from one of these symbiotic bacterial species, Rhizobium sp. Sin-1, significantly inhibits the synthesis of TNFα by human cells incubated with Escherichia coli LPS. Rhizobium Sin-1 LPS exerts these effects by competing with E. coli LPS for binding to LPS-binding protein and by directly competing with E. coli LPS for binding to human monocytes. Rhizobial lipid-A differs significantly from previously characterized lipid-A analogs in phosphate content, fatty acid acylation patterns, and carbohydrate backbone. These structural differences define the rhizobial lipid-A compounds as a potentially novel class of LPS antagonists that might well serve as therapeutic agents for the treatment of Gramnegative sepsis.

Original languageEnglish
Pages (from-to)41811-41816
Number of pages6
JournalJournal of Biological Chemistry
Volume277
Issue number44
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Rhizobium
Lipopolysaccharides
Cytokines
Lipid A
Escherichia coli
Monocytes
Bacteria
Tumor Necrosis Factor-alpha
Cells
Rhodobacter sphaeroides
Acylation
Gram-Negative Bacteria
Endotoxins
Fabaceae
Sepsis
Nitrogen
Fatty Acids
Phosphates
Carbohydrates

All Science Journal Classification (ASJC) codes

  • Biochemistry

Cite this

Vandenplas, M. L., Carlson, R. W., Jeyaretnam, B. S., McNeill, B., Barton, M. H., Norton, N., ... Moore, J. N. (2002). Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. Journal of Biological Chemistry, 277(44), 41811-41816. https://doi.org/10.1074/jbc.M205252200

Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. / Vandenplas, Michel L.; Carlson, Russell W.; Jeyaretnam, Benjamin S.; McNeill, Brian; Barton, Michelle H.; Norton, Natalie; Murray, Thomas F.; Moore, James N.

In: Journal of Biological Chemistry, Vol. 277, No. 44, 01.11.2002, p. 41811-41816.

Research output: Contribution to journalArticle

Vandenplas, ML, Carlson, RW, Jeyaretnam, BS, McNeill, B, Barton, MH, Norton, N, Murray, TF & Moore, JN 2002, 'Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production', Journal of Biological Chemistry, vol. 277, no. 44, pp. 41811-41816. https://doi.org/10.1074/jbc.M205252200
Vandenplas ML, Carlson RW, Jeyaretnam BS, McNeill B, Barton MH, Norton N et al. Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. Journal of Biological Chemistry. 2002 Nov 1;277(44):41811-41816. https://doi.org/10.1074/jbc.M205252200
Vandenplas, Michel L. ; Carlson, Russell W. ; Jeyaretnam, Benjamin S. ; McNeill, Brian ; Barton, Michelle H. ; Norton, Natalie ; Murray, Thomas F. ; Moore, James N. / Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. In: Journal of Biological Chemistry. 2002 ; Vol. 277, No. 44. pp. 41811-41816.
@article{a3d4f9a0393840fdbb70a0ce46a46b12,
title = "Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production",
abstract = "Endotoxin (lipopolysaccharide (LPS)), a component of Gram-negative bacteria, is among the most potent proinflammatory substances known. The lipid-A region of this molecule initiates the production of multiple host-derived inflammatory mediators, including cytokines (e.g. tumor necrosis factor-α (TNFα)). It has been a continuous effort to identify methods of interfering with the interaction between enteric LPS and inflammatory cells using natural and synthetic LPS analogs. Some of these LPS analogs (e.g. Rhodobacter spheroides LPS/lipid-A derivatives) are antagonists in human cells but act as potent agonists with cells of other species. Data reported here indicate that structurally novel LPS from symbiotic, nitrogen-fixing bacteria found in association with the root nodules of legumes do not stimulate human monocytes to produce TNFα. Furthermore, LPS from one of these symbiotic bacterial species, Rhizobium sp. Sin-1, significantly inhibits the synthesis of TNFα by human cells incubated with Escherichia coli LPS. Rhizobium Sin-1 LPS exerts these effects by competing with E. coli LPS for binding to LPS-binding protein and by directly competing with E. coli LPS for binding to human monocytes. Rhizobial lipid-A differs significantly from previously characterized lipid-A analogs in phosphate content, fatty acid acylation patterns, and carbohydrate backbone. These structural differences define the rhizobial lipid-A compounds as a potentially novel class of LPS antagonists that might well serve as therapeutic agents for the treatment of Gramnegative sepsis.",
author = "Vandenplas, {Michel L.} and Carlson, {Russell W.} and Jeyaretnam, {Benjamin S.} and Brian McNeill and Barton, {Michelle H.} and Natalie Norton and Murray, {Thomas F.} and Moore, {James N.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1074/jbc.M205252200",
language = "English",
volume = "277",
pages = "41811--41816",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "44",

}

TY - JOUR

T1 - Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production

AU - Vandenplas, Michel L.

AU - Carlson, Russell W.

AU - Jeyaretnam, Benjamin S.

AU - McNeill, Brian

AU - Barton, Michelle H.

AU - Norton, Natalie

AU - Murray, Thomas F.

AU - Moore, James N.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Endotoxin (lipopolysaccharide (LPS)), a component of Gram-negative bacteria, is among the most potent proinflammatory substances known. The lipid-A region of this molecule initiates the production of multiple host-derived inflammatory mediators, including cytokines (e.g. tumor necrosis factor-α (TNFα)). It has been a continuous effort to identify methods of interfering with the interaction between enteric LPS and inflammatory cells using natural and synthetic LPS analogs. Some of these LPS analogs (e.g. Rhodobacter spheroides LPS/lipid-A derivatives) are antagonists in human cells but act as potent agonists with cells of other species. Data reported here indicate that structurally novel LPS from symbiotic, nitrogen-fixing bacteria found in association with the root nodules of legumes do not stimulate human monocytes to produce TNFα. Furthermore, LPS from one of these symbiotic bacterial species, Rhizobium sp. Sin-1, significantly inhibits the synthesis of TNFα by human cells incubated with Escherichia coli LPS. Rhizobium Sin-1 LPS exerts these effects by competing with E. coli LPS for binding to LPS-binding protein and by directly competing with E. coli LPS for binding to human monocytes. Rhizobial lipid-A differs significantly from previously characterized lipid-A analogs in phosphate content, fatty acid acylation patterns, and carbohydrate backbone. These structural differences define the rhizobial lipid-A compounds as a potentially novel class of LPS antagonists that might well serve as therapeutic agents for the treatment of Gramnegative sepsis.

AB - Endotoxin (lipopolysaccharide (LPS)), a component of Gram-negative bacteria, is among the most potent proinflammatory substances known. The lipid-A region of this molecule initiates the production of multiple host-derived inflammatory mediators, including cytokines (e.g. tumor necrosis factor-α (TNFα)). It has been a continuous effort to identify methods of interfering with the interaction between enteric LPS and inflammatory cells using natural and synthetic LPS analogs. Some of these LPS analogs (e.g. Rhodobacter spheroides LPS/lipid-A derivatives) are antagonists in human cells but act as potent agonists with cells of other species. Data reported here indicate that structurally novel LPS from symbiotic, nitrogen-fixing bacteria found in association with the root nodules of legumes do not stimulate human monocytes to produce TNFα. Furthermore, LPS from one of these symbiotic bacterial species, Rhizobium sp. Sin-1, significantly inhibits the synthesis of TNFα by human cells incubated with Escherichia coli LPS. Rhizobium Sin-1 LPS exerts these effects by competing with E. coli LPS for binding to LPS-binding protein and by directly competing with E. coli LPS for binding to human monocytes. Rhizobial lipid-A differs significantly from previously characterized lipid-A analogs in phosphate content, fatty acid acylation patterns, and carbohydrate backbone. These structural differences define the rhizobial lipid-A compounds as a potentially novel class of LPS antagonists that might well serve as therapeutic agents for the treatment of Gramnegative sepsis.

UR - http://www.scopus.com/inward/record.url?scp=0036830128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036830128&partnerID=8YFLogxK

U2 - 10.1074/jbc.M205252200

DO - 10.1074/jbc.M205252200

M3 - Article

C2 - 12193596

AN - SCOPUS:0036830128

VL - 277

SP - 41811

EP - 41816

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 44

ER -